piccolo presynaptic cytomatrix proteinGenealiases: ACZ · PCH3
Q-omics provides the consensus-scored PCLO profile across patient tissues and cancer cell-line models. PCLO expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCLO is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PCLO protein abundance shows 23,886 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where PCLO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCLO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCLO survival associations across molecular data types. PCLO RNA expression shows survival associations in the most cancer types (25), followed by mutation status (14) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCLO RNA expression–survival associations across cancer types. High PCLO expression shows unfavorable associations in BLCA, THCA and LIHC, but favorable associations in KIRC, BRCA and PRAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCLO RNA expression.
This table summarizes PCLO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCLO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCLO shows lower tumor expression in THCA, KIRC, KICH and COAD and higher tumor expression in BLCA and LUSC. The THCA box plot shows higher PCLO RNA expression in normal versus tumor tissue (log2 FC = −1.437, t-test p < 0.001).
This table shows molecular features associated with PCLO in patient tissues and cancer cell lines. In patient samples, PCLO shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCLO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
